CIK 0000907654
- Non-accelerated filer
- Smaller reporting company
Oruka Therapeutics, Inc.
Sign in to watch- Ticker
- ORKA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 363855489
- Phone
- +1 650-606-7910
- Business address
- 855 OAK GROVE AVE., SUITE 100, MENLO PARK, CA, 94025
- Former names
- ARCA biopharma, Inc., NUVELO INC, HYSEQ INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,577,126
- in 17 filings, $20.2M under 10b5-1 plans
Net −$20,577,126. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Klein Lawrence Otto −$11.6M Chief Executive Officer sold 12% of stake
- Agarwal Arjun −$2.8M Senior Vice President, Finance sold 68% of stake
- Goncalves Joana −$2.0M Chief Medical Officer sold 41% of stake
- BALL KRISTINE M −$1.9M Director sold 100% of stake
- Quinlan Paul T −$1.7M General Counsel sold 40% of stake
Reading 88 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-12-14 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award · Stock Option (right to buy) | +27,500 | 27,500 | ||
| 2021-11-22 | Ozeroff Christopher David S.V.P., General Counsel | Purchase | +50,000 | $2.26 | $113K | 50,970 |
| 2020-12-21 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award · Stock Option (right to buy) | +55,000 | 55,000 | ||
| 2017-04-04 | Ozeroff Christopher David S.V.P., General Counsel | Sale | −418 | $2.41 | $1K | 17,517 |
| 2017-02-28 | Ozeroff Christopher David S.V.P., General Counsel | Sale | −465 | $2.61 | $1K | 17,935 |
| 2017-02-27 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award · Stock Option (right to buy) | +22,700 | 22,700 | ||
| 2017-02-16 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award · Stock Option (right to buy) | +24,000 | 24,000 | ||
| 2016-09-20 | Ozeroff Christopher David S.V.P., General Counsel | Sale | −1,185 | $2.89 | $3K | 18,400 |
| 2016-06-09 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award · Stock Option (right to buy) | +14,800 | 14,800 | ||
| 2016-06-09 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award · Stock Option (right to buy) | +30,200 | 30,200 | ||
| 2016-04-05 | Ozeroff Christopher David S.V.P., General Counsel | Sale | −366 | $3.52 | $1K | 19,585 |
| 2016-03-01 | Ozeroff Christopher David S.V.P., General Counsel | Sale | −458 | $3.51 | $2K | 19,951 |
| 2015-09-18 | Ozeroff Christopher David S.V.P., General Counsel | Sale | −1,129 | $6.32 | $7K | 20,409 |
| 2015-02-12 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award | +24,050 | 150,787 | ||
| 2015-02-12 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award · Stock Option (right to buy) | +12,950 | 12,950 | ||
| 2014-02-27 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award | +34,200 | $1.95 | $67K | 126,737 |
| 2014-02-27 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2013-09-17 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award | +75,000 | $1.38 | $104K | 92,537 |
| 2013-09-17 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award · Stock Option (right to buy) | +42,642 | 42,642 | ||
| 2012-10-22 | Ozeroff Christopher David SVP and General Counsel | Grant or award | +63,475 | $0.39 | $25K | 105,233 |
Page 1 of 2 · 27 trades